I. Introduction
Rheumatoid arthritis is a systemic, autoimmune disorder that primarily manifests as chronic synovial inflammation of multiple joints. As in the general population, both Diabetes Mellitus (DM) and Insulin Resistance (IR) appear to be independent risk factors for atherosclerotic CVD in patients with RA. Over the last few decades it has become increasingly apparent that chronic activation of the immune system, as observed in the pathogenesis of RA, is associated with corollary changes in intermediary metabolism, potentially leading to increased risk of cardiovascular disease. There is evidence of association of multiple immune regulatory components (including tumour necrosis factor and interleukin-6) in RA, IR, and type 2 diabetes mellitus. Disease associated reduction in lean muscle mass and sedentary lifestyle likely further contribute to IR in patients with RA (2) .
Impaired glucose metabolism (pre-diabetes and overt diabetes) is seen around 40 -45 % patients with RA. Hypertension is seen in more than 50 % of patients with RA and metabolic syndrome seen around 40% of patients. Central obesity is seen in >50 % of patients.
Both impaired beta cell function and insulin resistance is associated with impaired glucose handling in patients with rheumatoid arthritis. Abdominal obesity and RA disease activity are determinants of insulin resistance in patients with rheumatoid arthritis. Age and disease activity is associated with reduced beta cell function.
Tumour necrosis factor, a critical inflammatory cytokine in chronic active RA, has detrimental effects on lean muscle mass, resulting in sarcopenia and a relative increase in body adipose tissue, a condition known as rheumatoid cachexia. Levels of adiponectin, an adipocytokine, an inversely related to adiposity and IR, and adiponectin exerts favourable effects on insulin sensitivity and atherosclerosis. Adiponectin production by adipose cells is reduced by exposure to TNF-α, and low Adiponectin levels co-occur with characteristics of metabolic syndrome in patients with RA. Adipose tissue macrophages produce inflammatory cytokine, such as TNF-alpha and IL-6, thereby increasing inflammatory activity both locally and systemically. TNF-alpha can obstruct the bioactivity of the insulin by inhibiting tyrosine phosphorylation and subsequent activation of both the insulin receptor and insulin receptor substrate. This pivotal pro inflammatory cytokine also impedes insulinglucose-mediated uptake in skeletal muscle.
As with TNF-alpha, IL-6 appears to affect insulin-signalling pathways by diminishing the effect of insulin. Human adipocytes releases IL-6, and IL-6 production is increased in obesity, with higher secretion in visceral than subcutaneous tissue. Reduction of IL-6 levels by the administration of anti-IL6 antibodies increased insulin sensitivity. 
Synovial fluid analysis
It is inflammatory in nature with WBC count between 5000 to 50000 per cubic micro liter. Predominant cell type is neutrophil. RF, anti-CCP antibodies and immune complexes are also found in synovial fluid.
tnf-α (tumor necrosis factor):
Major cytokine in RA is TNF-α. It plays major role in induction of insulin resistance in the following ways 1. Induction of rheumatoid cachexia 2. By inhibiting tyrosine phosphorylation of insulin receptors block the effects of insulin (4). 3. In skeletal muscles block the insulin mediated glucose uptake (5). 4. Decrease adiponectin production (6). 5. Increase resistin production IL-6 another important cytokine in RA. Insulin resistance is induced in the same way as TNF-α (7). Other cytokines elevated in RA is IL-2 and IL-17 (8) .
Leptin:
Leptin produced by adipocytes. It plays role in glucose metabolism by 1. Decreasing insulin secretion,
Improving insulin sensitivity.
In chronic inflammatory conditions like RA, There is elevation of CRP. CRP induce leptin resistance by blocking receptor binding. It also has atherogenic effects by 1. Induction of endothelial dysfunction, 2. Stimulation of inflammatory reaction, 3. Oxidative stress, 4. Reduction of Paraxonase activity, 5. Platelet aggregation, 6. Smooth muscle cells modification (9) .
Adiponectin:
It has following favourable effects 1. Anti inflammatory, 2. Anti atherogenic, 3. Antidiabetic properties (10).
Production of adiponectin by adipocytes is decreased by TNF-αand other inflammatory cytokines which leads to insulin resistance, dyslipidemia and metabolic syndrome.
Resistin:
In contrast to other adipokines which are mainly produced by adipocytes, macrophages and monocytes of peripheral blood produce Resistin (11) . TNF-α induce expression of Resistin gene in mononuclear cells. It has 1. Pro inflammatory properties -up-regulate the TNF-α and IL-6 of mononuclear cells of peripheral blood (12) . 2. Induce hepatic IR by increased hepatocellular production of TNF-α and IL-6. VISFATIN (colony enhancing factor of pre-B-cell):
TNF-α and interleukin-6 increase visfatin production. High levels of visfatin is associated with hyperglycemia and insulin resistance (13) .
Lipotoxicity:
Beta cell function is impaired by adipokines and excess non esterified fatty acids which released by enlarged adipose cells. Steroids in high dose also impair beta cell activity (19) .
Vitamin d:
Vitamin D deficiency in patients with RA is associated with hyperlipidemia and metabolic syndrome. Supplementation of vitamin D improves dyslipidemia and decrease metabolic syndrome (14) .
Finally it is concluded that patient with RA has high risk of impaired beta cell function and insulin function which potentially leads to impaired glucose metabolism and acceleration of atherosclerosis. patients. Compared with healthy controls, the patients had impaired glucose handling and enhanced insulin response (p< 0.01). Impaired glucose handling is found to be due to insulin resistance. Normalization of inflammatory activity with treatment improved insulin resistance and normalized glucose metabolism (15). 2. A study was conducted in Sweden at 1987 in the department of general medicine by Karin L.G. Svenson in 45 untreated rheumatoid arthritis patients. In the patient group, the basal serum insulin concentration (p< 0.001) and the maximum insulin response to glucose loading (p<.01) were significantly higher. The rine output of cortisol and catecholamines was normal. So stress reaction can"t be reason for impaired glucose metabolism (16). 3. A study was conducted by Lundqvist at 1987 in 42 patients with RA. Changes in glucose metabolism was monitored after institution of antirheumatic therapies. A reversal of glucose handling to normal was observed in patients treated with prednisolone 20 mg daily (n=16, p<.001), chloroquine (n=7), penicillamine (n=4), Azathioprine and cyclophosphamide (n=7) (17 
Anti-tnf agents:
1. The benefits of treatment with TNFα antagonists as a class appear to extend beyond control of joint disease activity. 2. With prolonged anti-TNF treatment the partial restoration of metabolic function and alleviation of IR are becoming increasingly evident (27) (28).
Classical drugs are infliximab, Etanercept, Adalimumab. Anti-TNF therapy carries risk of reactivation of latent TB, bacterial and fungal infections.
Anakinra:
The recombinant form of the naturally occurring IL-1 receptor antagonist. Due to high rate of serious infections it should not be combined with an anti-TNF drug.
Abatacept:
-It inhibits the co-stimulation of T cells by blocking CD28-CD80/86 interactions.
-It also inhibit the function of antigen-presenting cells by reverse signaling through CD80 and CD86.
Rituximab:
-Chimeric monoclonal antibody directed against CD20.
-It carries risk of progressive multifocal leukoencephalopathy.
Tocilizumab:
-Humanized monoclonal antibody directed against soluble and membrane forms of IL-6 receptor.
Tofacitinib:
-Small-molecule inhibitor that primarily inhibits JAK1 AND JAK3.
Materials and methods: Study population:
This study is to be conducted in 50 newly detected Rheumatoid arthritis patients attending Rheumatology CLINIC at Govt Rajaji hospital, Madurai. Random blood glucose, fasting plasma glucose, 2-hours plasma glucose in OGTT, urine sugar and fasting lipid profile is done in all patients. NCEP:ATPIII 2001 criteria is used to define metabolic syndrome. ADA, 2014 guidelines is used to define pre-diabetes and diabetes. Impaired glucose metabolism includes both pre-diabetic and diabetic. 
IV.
Statistical metthods:
The data collected during the study was formulated into a master chart in Microsoft office excel and statistical analysis was done with help of computer using statistical software package SPSS V.17 for windows. Using this software, frequencies, range, mean, standard deviation and "p "were calculated through Student "t" test, One way ANOVA, Pearson Correlation and Chi square test . P value of < 0.05 was taken as significant. 
V. Results

Gender Distribution Of Ra
In our study, male constituted nearly 24% (n=12) and female 76% (n=38). This study shows RA is more common in female than in male (p<0.001) which is statistically significant. Female to male ratio is 3:1. 
Age Distribution Of Ra
In our study among 50 patients, 16% (n=8) of patients were less than 35 years, 36 % (n=18) of patients are between 36-45 years and 48% (n=24) of patients are >45 years. It shows that incidence of RA increasing with age. Majority of patients were above 45 years. 
Age (years)
Rheumatoid Factor
In our study among 50 patients, 88% (n=44) of patients were Rheumatoid factor positive and 12 % (n=6) of patients were Rheumatoid factor negative. So sensitivity of Rheumatoid factor in our study is 88%. Most patients were RF positive which is statistically significant (p<0.001). 
Obesity In Ra Patients
Obesity
In our study, 68 % (n=34) of patients were obese (p<0.005) and 32 % (n=16) of patients were non obese. Hence statistically significant number of RA patients had central obesity. 
Gender Distribution Of Obesity
Obesity Vs Gender
In our study among 12 male patients, 67 % (n=8) male were obese and among 38 female patients, 68 % (n=26) were obese. Both male (p<0.008) and female (p<0.005) RA patients had significant obesity. Female Patients had slightly high prevalence of obesity. 
Age Distribution Of Obesity
Hypertension
In our study among 50 patients, 64 % (n=32) of patients were hypertensive and 36 % (n=18) of patients were normotensive. Significant number of RA patients were hypertensive (p<0.030). HYPERTENSION  FREQUENCY  PERCENTAGE  Male  Female  Male  Female  YES  7  25  58  66  NO  5  13  42  34  Total  12  38  100  100 In our study among 12 males, 58 % (n=7) of males were hypertensive and among 38 females, 66 % (n=25) were hypertensive. More number of female patients (p<0.030) were hypertensive compared to male patients. 
Gender Distribution Of Hypertension
Htn Vs Gender Age Distribution Of Hypertension In Ra
Glucose Metabolism
In our study 66 % (n=33) of patients had impaired glucose metabolism and 34 % (n=17) of patients had normal glucose metabolism. Impaired glucose metabolism is statistically significant (p<0.012). In our study out of 8 males aged < 35 years, 3 (38%) had impaired glucose metabolism and out of 18 males aged 35-45 years, 12 (67%) had significant impaired glucose metabolism (p<0.008). Out 24 patients (age >45 years), 18 (75%) had impaired glucose metabolism which is statistically significant (p<0.001). Compared with patients aged <35 (38%), patients with age >45 years had significant impaired glucose metabolism (p<0.008) which shows that prevalence of impaired glucose metabolism increasing with age. 
Gender Distribution Of Impaired Glucose Metabolism In Ra
Impaired Glucose Metabolism Vs Age Frank Diabetes In Ra
Diabetes
In our study 11(22%) had diabetes out of 50 patients. Among 66% of patients with impaired glucose metabolism (pre-diabetes and diabetes), frank diabetes contributed 22%. Statistically it is not significant. DIABETES VS  PERCENTAGE  GENDER  FREQUENCY  Male  Female  Male  Female  Diabetic  2  9  16  24  Non Diabetic  10  29  84  76  Total  12  38  100  100 In our study 2 (16%) males had diabetes out of 12 and 12 (24%) females had diabetes out of 38. Prevalence of diabetes is higher in female RA patients. 
Gender Distribution Of Diabetes In Ra
Age Distribution Of Diabetes In Ra
Dyslipidemia
In our study 29 (58%) out of 50 patients had dyslipidemia. Though significant number of patients had dyslipidemia P value is <0.236 (statistically not significant).
Gender distribution of dyslipidemia in ra patients. GENDER  FREQUENCY  PERCENTAGE  Male  Female  Male  Female  Dyslipidemia  4  25  33  66  Non Dyslipidemia  8  13  67  34  Total  12  38  100  100 In our study 4 (33%) out of 12 male patients had dyslipidemia and 25 (66%) out of 38 female patients had dyslipidemia. Compared with male, prevalence of dyslipidemia is higher in female patients (p<0.012 significant). In our study 3 (38%) out of 8 patients in the age group of <35 years had dyslipidemia and 10 (56%) out of 18 patients in the age group of 35-45 years had dyslipidemia. In the age group of > 45 years 16 (67%) out of 24 patients had dyslipidemia. Prevalence of dyslipidemia is increasing with age with maximum incidence in patients >45 years (p<0.047 significant). 
DYSLIPIDEMIA VS
Metabolic Syndrome In Ra
Metabolic Syndrome
In our study 24 (48%) out of 50 patients had metabolic syndrome according to NCEP:ATP III 2001 but P value is <0.838 (not significant). Male  Female  Male  Female  Yes  4  20  33  53  No  8  18  67  47  Total  12  38  100  100 In our study 4 (33%) out of 12 male patients full filled the criteria for metabolic syndrome and in female patients 20 (53%) out of 38 full filled the criteria for metabolic syndrome. Female patients had higher prevalence of metabolic syndrome but it is not significant statistically. METABOLIC  SYNDROME  VS AGE  FREQUENCY  PERCENTAGE  < 35  35 -45  > 45  <35  35-45  >45  Yes  2  7  15  25  39  63  No  6  11  9  75  61  37  Total  8  18  24  100  100  100 In our study 7 (39%) out of 18 patients full filled the criteria for metabolic syndrome in the age group of 35-45 years and 15 (63%) out of 24 patients full filled the criteria for metabolic syndrome in the age group of >45 years (p<0.045 significant). Increasing age is found to be risk factor for metabolic syndrome. In our study 73 % of RF positive patients had obesity and 32 % of RF negative patients had obesity (P<0.002 significant). 68 % of RF positive patients were hypertensive (P<0.005 significant) and 32 % of RF negative patients were hypertensive. 71 % of RF positive patients had impaired glucose metabolism (P<0.002 significant) and 32 % of RF negative patients had impaired glucose metabolism. Dyslipidemia was seen 64 % of RF positive (P<0.001 significant) and 16% of RF negative patients. Criteria for metabolic syndrome was full 
Gender Distribution Of Metabolic Syndrome
Metabolic Syndrome Vs Gender Distribution Age Distribution Of Metabolic Syndrome In Ra
Rf Positive Vs Negative
Duration Of Symptoms
In our study group 28 % (n=14) of patients had duration of symptoms < 6 months and 50 % (n=25) of patients had duration of symptoms 6 -12 months. 22 % (n=11) of patients were symptomatic > 12 months. Majority of patients were symptomatic for 6 to 12 months. In our study patients who were symptomatic for less than 6 months had prevalence of obesity-64% (P<0.045 significant), hypertension-57%, impaired glucose metabolism-57%, dyslipidemia-36% and metabolic syndrome-29%. Patients with symptoms 6-12 month had prevalence of obesity-68% (P<0.008 significant), 
Distribution Of Duration Symprtoms
Joint Involvement
In our study 26 % (n=13) patients had involvement of 1-3 small joints, 62% (n=31) of patients had 4-10 and 12 % (n=6) have > 10 small joint involvement. In our study out of 6 patients with involvement of 1-3 small joint involvement, obesity and impaired glucose metabolism were seen in 3 patients. 2 patients had hypertension and dyslipidemia. Metabolic syndrome was seen in one patients.
Joint Involvement Vs Co-Morbid Illness
In patients with involvement of 4-10 small joint out (n=31), 65% of patients had impaired glucose metabolism and hypertensive (p<0.023 significant). Obesity was seen 68% of patients (p<0.008 significant). Dyslipidemia and metabolic syndrome was seen 58%, 45% of patients respectively.
Out of 13 patients with involvement of >10 small joint, 77 % of patients had hypertension, impaired glucose metabolism and obesity (p<0.001 significant). 69% of patients have dyslipidemia and metabolic syndrome (p<0.08 significant).
So patients with more number of joint involvement and increasing disease activity are prone to impaired glucose metabolism, hypertension and metabolic syndrome. Hence it is important to treat the disease in early stage.
Joint Involvement
IV. IV. Discussion
The study was conducted in the patients who attended Rheumatologic clinic, Govt Rajaji hospital, Madurai. Diagnosis of Rheumatoid arthritis was made according to ACR-EULAR 2010 criteria. Only new diagnosed treatment naïve patients were included in this study. After applying exclusion criteria 50 patients were selected for study.
Out of 50 patients 38 patients were female and 12 patients were male (3:1). It is consistent with previous studies because autoimmune nature of disease RA is more common female.
Rheumatoid factor was positive in 44 patients and negative in 6 patients. Sensitivity of Rheumatoid factor was 88% (p<0.001 significant). Negative test for Rheumatoid factor doesn"t rule out diagnosis of Rheumatoid arthritis because diagnostic sensitivity of RF is around 80% only.
Out of 50 patients 8 patients were <35 years, 18 patients 35-45 years and 24 patients >45 years. Mean age of patient in this study was 42.06 years. With increasing age prevalence of RA was increasing.
As like previous studies conducted by Roubenoff and colleagues, central obesity was seen in 68% of patients which statistically significant (p<0.005 significant). In our study women were more prone for central obesity (Rheumatoid cachexia). It is consistent with previous studies like conducted by Giles et al., . Prevalence of obesity was increasing with increasing age, long duration of symptoms, more number of joint involvement and high degree of inflammation. Because central obesity one of the key factor responsible for insulin resistance early diagnosis of RA and introduction of treatment is important to control inflammation. Controlling of inflammation improves obesity.
In our study 66% of patients had impaired glucose metabolism which was statistically significant (p<0.012). Out of 66% of patients with impaired glucose metabolism (pre-diabetes and diabetes), 22 % of patients had frank diabetes. As we knew from previous studies like conducted by Patrick H. Dessein et al., age, high grade inflammation and long duration of disease are important risk factor for impaired glucose metabolism. In our study also impaired glucose metabolism was more prevalent with increasing age (>45 years 75%), long duration of disease (>12 months 73%) and high grade of inflammation (>10 small joint involvement 77%) which is consistent with previous studies. By controlling inflammation with early diagnosis and introduction of treatment we can improve impaired glucose metabolism.
In our study hypertension was seen 64 % of patients (p<0.030 significant) which is consistent with previous studies like conducted by Dessein et al., . In previous studies like conducted by chung et al., reported presence of metabolic syndrome in DOI: 10.9790/0853-150907108134 www.iosrjournals.org 131 | Page 42 % patients with long standing disease. In our study also dyslipidemia and metabolic syndrome was seen in 58 % and 48 % of patients respectively which is consistent with previous studies.. All these risk factors for cardiovascular disease was seen in patients with long standing disease and high grade inflammation. In our study compared with Rheumatoid factor negative patients, patients with Rheumatoid factor positive were more prone to impaired glucose metabolism, hypertension and metabolic syndrome. Hence patients with Rheumatoid factor positive were more prone to cardiovascular disease.
V. Limitation
-Sample size is small.
-The study population involved patients seeking medical care in our hospital which is a tertiary care center and hence they may not represent the general population.
VI. Conclusion
In our study obesity, impaired glucose metabolism, hypertension, dyslipidemia and metabolic syndrome were seen in 68 %, 66 %, 64 %, 58 % and 48 % of patients respectively.
-Long duration of disease and disease activity is important risk of factor impaired glucose metabolism, obesity, dyslipidemia, hypertension and metabolic syndrome. -Impaired glucose metabolism and metabolic syndrome carries high risk of cardiovascular disease.
-Early diagnosis and early introduction of treatment will reduce disease activity and control inflammation.
-By controlling inflammation we can reduce risk of impaired glucose metabolism and metabolic syndrome.
-We can improve long term survival of Rheumatoid arthritis patients.
VII. Summary
This prospective observational study was conducted to identify the prevalence of impaired glucose metabolism and other to cardiovascular risk factors in Rheumatoid arthritis patients.
With 50 patients were selected carefully and were evaluated on clinical and laboratory aspects after institutional ethical clearance with an informed consent. The data were entered in Microsoft Excel spread sheet and analysed statistically.
Prevalence of central obesity, impaired glucose metabolism, hypertension, dyslipidemia and metabolic syndrome is seen 68 %, 66 %, 64 %, 58 % and 48% of newly detected treatment naive Rheumatoid arthritis patients.
Age, disease activity and duration of disease is found to be important key factor in induction of impaired glucose metabolism and other cardiovascular risk factors.
In our study many of the patients are diagnosed after one year of symptoms. Hence early diagnosis is important to prevent this cardiovascular risk factors. Because disease activity correlate with cardiovascular risk factors early control of disease activity is important. atient with obesity shows poor response to Anti-TNF agents. So measures to reduce to obesity like exercise should be considered along with DMARDs.
So with early diagnosis and early introduction of treatment we can reduce the prevalence of impaired glucose metabolism, hypertension, obesity, dyslipidemia and metabolic syndrome in Rheumatoid arthritis patient. With all these measures we can reduce the risk of cardiovascular disease and improve long term survival of Rheumatoid arthritis patients.
